Pipeline: External Programs
Allarity is actively engaged in external program collaborations to advance these promising clinical programs through development.
DeflexifolTM
DeflexifolTM, an optimized all-in-one formulation of the chemotherapeutic agent 5-fluorouracil (5FU) and its biomodulator leucovorin (LV), is being developed by FivepHusion including Allarity’s DRP® companion diagnostics in the clinical trial design.
LiPlaCis®
LiPlaCis®, a target controlled liposome formulation of one of the world’s most widely used chemotherapeutic agents, cisplatin. The specific LiPlaCis formulation allows delivery of LiPlaCis directly to the tumor site where is it needed. Allarity completed the initial Phase 2, DRP-guided proof-of-concept trial in metastatic breast cancer that showed promising results. LiPlaCis had been out licensed to Chosa Oncology AB. Chosa will advance the development of LiPlaCis® in late stage metastatic breast cancer in an expanded phase 2 trial.
